BioCryst Pharmaceuticals has announced plans to discontinue its internal discovery programmes and close its Discovery Center of Excellence facility in Birmingham, Alabama by the end of 2026.  The company says the moves are part of an ongoing strategic evolution to strengthen its rare disease pipeline.   It has determined that prioritising external innovation will be the […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!